Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia (CLL).
This was an analysis of a phase Ib/II study that included brief treatment with obinutuzumab (Gazyva) and ibrutinib (Imbruvica) prior to venetoclax (Venclexta). After 1 month of obinutuzumab, patients had dramatically reduced lymphocyte count. Lymphocytosis wasseen with the addition of ibrutinib, however, the lymphocyte count was nowhere near what it was prior to the patient receiving obinutuzumab, Rogers explains.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More